The Avacta Group Plc (LON: AVCT) share price rose 12.7% after announcing that it had completed the ALS-6000-101 Sixth Dose Escalation and Clinical Update. The company noted that the excellent safety profile of AVA6000 continues to be observed in the sixth dose escalation cohort.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
The firm revealed a significant reduction in tumour volume confirmed in a patient with soft tissue sarcoma. The upcoming Cohort 7 will be the final dose escalation cohort in the Phase 1a clinical trial that doses patients every three weeks.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading stocks, forex, cryptos, and beyond. Dive in and test their capabilities with complimentary demo accounts today!
- eToro Top stock trading platform with 0% commission – Read our Review
- Tickmill Regulated by the FCA – Read our Review
- Admirals (Admiral Markets) More than 4500 stocks & ETFs available – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Avacta has a revamped regulatory strategy that could fast-track the pivotal Phase 2 study launch in 2024. The company intends to release the detailed Phase 1a study results in Q4 2023. The company’s AVA6000 is a tumour-targeted form of doxorubicin chemically modified with Avacta's pre|CISION™ platform.
AVA6000 is designed to reduce systemic side effects of chemotherapy by targeting the release of the active chemotherapy to tumour tissue. Avacta has now dosed 35 patients with a range of advanced and/or metastatic solid tumours at clinical trials in the UK and United States.
Patients in cohort 6 well tolerated the drug despite receiving 2.79 times the typical dose of doxorubicin. The company continues to observe a clinically significant reduction in the toxicities usually associated with standard doxorubicin chemotherapy.
Based on the very favourable safety profile of AVA6000, the Safety Data Monitoring Committee (SDMC) has recommended a continuation of the seventh dose cohort at 385 mg/m2, equivalent to approximately 3.5 times the standard dose of doxorubicin.
The Company and its advisers have decided that Cohort 7 will be the final dose escalation cohort in the ALS-6000-101 Phase 1a safety study for three weekly doses.
Avacta Group’s CEO, Dr Alastair Smith, commented: “I believe that we are on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients. The safety and initial efficacy signals emerging from the data in the AVA6000 Phase 1 study are very encouraging indeed. The pre|CISIONTM platform is doing exactly what it was designed to do – target the release of active chemotherapy to the tumour tissue, sparing healthy tissues and improving the safety and tolerability of the drug whilst delivering potentially superior efficacy.”
Avacta share price.
The Avacta share price rose 12.74% to trade at 119.25p, from Monday’s closing price of 106.00p.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.